Anti-vascular endothelial growth factor pharmacotherapy for diabetic macular edema: A report by the American academy of ophthalmology

Ophthalmology

Volumn 119, Issue 10, 2012, Pages 2179-2188

  Ho, Allen C ^a   Scott, Ingrid U ^a   Kim, Stephen J ^a   Brown, Gary C ^a   Brown, Melissa M ^a   Ip, Michael S ^a   Recchia, Franco M ^a  

^a American Academy of Ophthalmology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; TRIAMCINOLONE; UNCLASSIFIED DRUG; VEGF TRAP EYE;

COCHRANE LIBRARY; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DIABETIC MACULAR EDEMA; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENDOPHTHALMITIS; FOLLOW UP; GLIOBLASTOMA; HUMAN; KIDNEY CARCINOMA; LASER COAGULATION; LONG TERM CARE; LUNG NON SMALL CELL CANCER; MEDLINE; META ANALYSIS; MULTICENTER STUDY (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSPECTIVE STUDY; PUBLICATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINA VEIN OCCLUSION; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; UVEITIS; VISUAL ACUITY;

EID: 84867096307     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2012.07.058     Document Type: Article

References (39)

1. American Academy of Ophthalmology Retina/Vitreous Panel Preferred Practice Pattern Guidelines Diabetic Retinopathy 2008 American Academy of Ophthalmology San Francisco, CA 4 http://one.aao.org/CE/PracticeGuidelines/PPP. aspx Accessed April 9, 2012
2. C.C. Cowie, K.F. Rust, D.D. Byrd-Holt Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999-2002 Diabetes Care 29 2006 1263 1268
3. International Diabetes Federation Fact Sheet: Diabetes and Eye Disease http://www.idf.org/fact-sheets/diabetes-eye-disease Accessed April 9, 2012
4. Early Treatment Diabetic Retinopathy Study Research Group Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report number 1 Arch Ophthalmol 103 1985 1796 1806
5. L.P. Aiello, R.L. Avery, P.G. Arrigg Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders N Engl J Med 331 1994 1480 1487
6. R.L. Avery Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment Retina 26 2006 352 354
7. U.S. Food and Drug Administration Center for Drug Evaluation and Research Application number: 21-756 Approved labeling. Macugen (pegaptanib sodium injection) http://www.accessdata.fda.gov/drugsatfda-docs/label/2006/021756s006, s0071bl.pdf 2006 7, 10. Accessed April 9, 2012
8. U.S. Food and Drug Administration Center for Drug Evaluation and Research BLA application number: 125156 Approved labeling. Lucentis (ranibizumab injection) http://www.accessdata.fda.gov/drugsatfda-docs/label/2006/1251561bl. pdf 2006 1. Accessed April 9, 2012
9. U.S. Food and Drug Administration Center for Drug Evaluation and Research BLA application number: 125156/053 Lucentis (ranibizumab injection) http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/125156s0531bl.pdf 2010 1. Accessed April 9, 2012
10. U.S. Food and Drug Administration Center for Drug Evaluation and Research U.S. BLA 125085/168 Amendment Final labeling text. Avastin (bevacizumab) http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/125085s01681bl.pdf 2009 1. Accessed April 9, 2012
11. U.S. Food and Drug Administration Center for Drug Evaluation and Research Eylea (aflibercept) Injection [package insert] 2011:1 http://www.accessdata. fda.gov/drugsatfda-docs/label/2011/1253871bl.pdf Accessed April 9, 2012
12. J.A. Chapman, C. Beckey Pegaptanib: a novel approach to ocular neovascularization Ann Pharmacother 40 2006 1322 1326
13. J.A. Web Genentech decision expands access to bevacizumab Ophthalmol Times January 15, 2008
14. Oxford Centre for Evidence-Based Medicine - Levels of evidence (March 2009) http://www.cebm.net/index.aspx?o=1025 Accessed April 9, 2012
15. M.J. Elman, L.P. Aiello, R.W. Beck Diabetic Retinopathy Clinical Research Network Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema Ophthalmology 117 2010 1064 1077
16. M.J. Elman, N.M. Bressler, H. Qin Diabetic Retinopathy Clinical Research Network Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema Ophthalmology 118 2011 609 614
17. P. Mitchell, F. Bandello, U. Schmidt-Erfurth RESTORE Study Group The RESTORE Study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema Ophthalmology 118 2011 615 625
18. J. Googe, A.J. Brucker, N.M. Bressler Diabetic Retinopathy Clinical Research Network Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation Retina 31 2011 1009 1027
19. Q.D. Nguyen, D.M. Brown, D.M. Marcus RISE and RIDE Research Group Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE Ophthalmology 119 2012 789 801
20. M.B. Sultan, D. Zhou, J. Loftus Macugen 1013 Study Group A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema Ophthalmology 118 2011 1107 1118
21. Q.D. Nguyen, S.M. Shah, J.S. Heier READ-2 Study Group Primary end point (six months) results of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) study Ophthalmology 116 2009 2175 2181
22. P. Massin, F. Bandello, J.G. Garweg Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study Diabetes Care 33 2010 2399 2405
23. M. Soheilian, A. Ramezani, B. Bijanzadeh Intravitreal bevacizumab (Avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema Retina 27 2007 1187 1195
24. M. Soheilian, A. Ramezani, A. Obudi Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema Ophthalmology 116 2009 1142 1150
25. Macugen Diabetic Retinopathy Study Group A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema Ophthalmology 112 2005 1747 1757
26. Diabetic Retinopathy Clinical Research Network A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema Ophthalmology 114 2007 1860 1867
27. K.A. Solaiman, M.M. Diab, M. Abo-Elenin Intravitreal bevacizumab and/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema Retina 30 2011 1638 1645
28. D.S. Lam, T.Y. Lai, V.Y. Lee Efficacy of 1.25 mg versus 2.5 mg intravitreal bevacizumab for diabetic macular edema: six-month results of a randomized controlled trial Retina 29 2009 292 299
29. R. Rajendram, S. Fraser-Bell, A. Kaines A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3 Arch Ophthalmol 2012 Apr 9 [Epub ahead of print]
30. D.V. Do, U. Schmidt-Erfurth, V.H. Gonzalez The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema Ophthalmology 118 2011 1819 1826
31. J.F. Arevalo, J.G. Sanchez, L. Wu Pan-American Collaborative Retina Study Group (PACORES) Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months Ophthalmology 116 2009 1488 1497
32. C. Haritoglou, D. Kook, A. Neubauer Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema Retina 26 2006 999 1005
33. M.S. Ip, I.U. Scott, G.C. Brown Ophthalmic Technology Assessment Committee Retina/Vitreous Panel Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology Ophthalmology 115 2008 1837 1846
34. D.M. Brown, P.K. Kaiser, M. Michels ANCHOR Study Group Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 2006 1432 1444
35. P.J. Rosenfeld, D.M. Brown, J.S. Heier MARINA Study Group Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 2006 1419 1431
36. D.S. Boyer, J.S. Heier, D.M. Brown A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration Ophthalmology 116 2009 1731 1739
37. D.F. Martin, M.G. Maguire, G.S. Ying CATT Research Group Ranibizumab and bevacizumab for neovascular age-related macular degeneration N Engl J Med 364 2011 1897 1908
38. W.E. Smiddy Economic considerations of macular edema therapies Ophthalmology 118 2011 1827 1833
39. Q.D. Nguyen, S.M. Shah, A.A. Khwaja READ-2 Study Group Two-year outcomes of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) study Ophthalmology 117 2010 2146 2151